Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 adaptive multiple‑dose IV AMB-05X in tenosynovial giant cell tumor
2020-004870-22Phase 2Completed
- Sponsor
- AmMax Bio
- Start
- Dec 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of ABM-05X in tenosynovial giant cell tumor (TGCT) and giant cell tumor of tendon sheath (GCTTS), sponsored by AmMax Bio. Primary endpoint: Treatment-emergent adverse events. Started Dec 2020; status: completed.
02
Drugs
ABM-05X
03
Conditions
tenosynovial giant cell tumor (TGCT)giant cell tumor of tendon sheath (GCTTS)
Beyond the preview
Go deeper on 2020-004870-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-004870-22.